RxDoctor Payments Data

Olga Stetsyuk, DO

Glaucoma Specialist · Concord, NHNPI 1689064719

Payments from drug & device makers

$2,241in general payments, 2019–2025

Across 65 payments — averaging $34.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$840
  • Bausch & Lomb Americas Inc.$464
  • AbbVie$330
  • NEW World Medical,inc.$241
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$163
  • Ivantis, Inc$104
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$2,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in New Hampshireto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$374,837
Medicare patients
629
Services billed
3,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost238$148,663
RhopressaNetarsudil Mesylate93$63,604
RocklatanNetarsudil Mesylat/Latanoprost87$61,696
VyzultaLatanoprostene Bunod112$57,134
Alphagan PBrimonidine Tartrate93$37,725
CombiganBrimonidine Tartrate/Timolol69$24,984
Brimonidine Tartrate641$18,835
RestasisCyclosporine12$17,201
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol100$17,073
SimbrinzaBrinzolamide/Brimonidine Tart38$16,204
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat636$11,879
ProlensaBromfenac Sodium20$11,738
Latanoprost1,131$10,583
Travoprost74$10,274
Methazolamide41$9,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan, Restasis$330$228,573412 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$32$125,300180 claims
Bausch & Lomb Americas Inc.Vyzulta$464$57,134112 claims
AlconSimbrinza$840$16,20438 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$163$11,73820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in New Hampshireon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Concord

Where these figures come from

Is this you, or does something look wrong? →